(CGON) CG Oncology, Common stock - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 5.698m USD | Total Return: 312.6% in 12m
Cancer Therapies, Bladder Cancer, Clinical Trials
Total Rating 40
Safety 36
Buy Signal 1.67
Biotechnology
Industry Rotation: +3.7
Industry Rotation: +3.7
Market Cap:
5.70B
Avg Turnover: 109M USD
Avg Turnover: 109M USD
ATR:
4.60%
Peers RS (IBD): 87.3
Peers RS (IBD): 87.3
Risk 5d forecast
Volatility56.0%
Rel. Tail Risk-8.06%
Reward TTM
Sharpe Ratio2.34
Alpha248.38
Character TTM
Beta0.995
Beta Downside0.793
Drawdowns 3y
Max DD67.47%
CAGR/Max DD0.50
EPS (Earnings per Share)
EPS CAGR: -39.21%
EPS Trend: -85.2%
EPS Trend: -85.2%
Last SUE: -0.20
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 664.91%
Rev. Trend: 63.4%
Rev. Trend: 63.4%
Last SUE: 1.75
Qual. Beats: 2
Qual. Beats: 2
Warnings
Share dilution 19.3% YoY - potential capital distress
High Debt while negative Cash Flow
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Altman Z'' -7.19 < 1.0 - financial distress zone
Tailwinds
Squeeze Supp Ema20
Description: CGON CG Oncology, Common stock
CG Oncology, Inc. (CGON) is a late-stage clinical biopharmaceutical company focused on bladder-sparing therapies for bladder cancer. The companys business model centers on developing and commercializing novel treatments for a specific disease area within oncology.
Its lead product, BOND-003, is in Phase 3 clinical trials for high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The biotechnology sector is characterized by lengthy and costly drug development processes, with only a small percentage of drug candidates successfully reaching market.
Other pipeline candidates include CORE-001 (Phase 2 for BCG-unresponsive NMIBC in combination), CORE-002 (combination therapy for muscle-invasive bladder cancer), PIVOT-006 (Phase 3 monotherapy for intermediate-risk NMIBC), and CORE-008 (Phase 2 for high-risk NMIBC). These therapies are designed to address various stages and types of bladder cancer, a disease with significant unmet medical needs. Further research on platforms like ValueRay can provide additional context on CGONs market position and clinical trial progress.
- Phase 3 trial results for BOND-003 impact stock
- Regulatory approval for bladder cancer therapies
- Competition from other bladder cancer treatments
- Clinical trial progress for CORE-001 and PIVOT-006
Piotroski VR‑10 (Strict)
0.0
| Net Income: -161.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.17 > 0.02 and ΔFCF/TA -6.28 > 1.0 |
| NWC/Revenue: 18.0k% < 20% (prev 64.3k%; Δ -46.3k% < -1%) |
| CFO/TA -0.17 > 3% & CFO -132.3m > Net Income -161.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 24.63 > 1.5 & < 3 |
| Outstanding Shares: last quarter (77.3m) vs 12m ago 19.26% < -2% |
| Gross Margin: -15.02% > 18% (prev 0.99%; Δ -1.60k% > 0.5%) |
| Asset Turnover: 0.52% > 50% (prev 0.15%; Δ 0.37% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
Altman Z''
-7.19
| A: 0.92 (Total Current Assets 759.5m - Total Current Liabilities 30.8m) / Total Assets 791.6m |
| B: -0.48 (Retained Earnings -379.0m / Total Assets 791.6m) |
| C: -0.22 (EBIT TTM -168.7m / Avg Total Assets 773.2m) |
| D: -9.72 (Book Value of Equity -379.0m / Total Liabilities 39.0m) |
| Altman-Z'' Score: -7.19 = D |
Beneish M
1.00
| DSRI: 0.25 (Receivables 688k/781k, Revenue 4.04m/1.14m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 127.3 (AQ_t 0.02 / AQ_t-1 0.00) |
| SGI: 3.55 (Revenue 4.04m / 1.14m) |
| TATA: -0.04 (NI -161.0m - CFO -132.3m) / TA 791.6m) |
| Beneish M-Score: 73.04 (Cap -4..+1) = D |
What is the price of CGON shares?
As of April 08, 2026, the stock is trading at USD 69.81 with a total of 1,684,842 shares traded.
Over the past week, the price has changed by +3.15%, over one month by +13.90%, over three months by +64.45% and over the past year by +312.59%.
Over the past week, the price has changed by +3.15%, over one month by +13.90%, over three months by +64.45% and over the past year by +312.59%.
Is CGON a buy, sell or hold?
CG Oncology, Common stock has received a consensus analysts rating of 4.40.
Therefore, it is recommended to buy CGON.
- StrongBuy: 5
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CGON price?
| Analysts Target Price | 83.3 | 19.3% |
CG Oncology, Common stock (CGON) - Fundamental Data Overview
as of 04 April 2026
P/S = 1410.3187 P/B = 7.4966
Revenue TTM = 4.04m USD
EBIT TTM = -168.7m USD
EBITDA TTM = -167.3m USD
Long Term Debt = 3.00m USD (from longTermDebt, last quarter)
Short Term Debt = 915k USD (from shortTermDebt, last quarter)
Debt = 7.02m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -735.1m USD (recalculated: Debt 7.02m - CCE 742.2m)
Enterprise Value = 4.96b USD (5.70b + Debt 7.02m - CCE 742.2m)
Interest Coverage Ratio = unknown (Ebit TTM -168.7m / Interest Expense TTM 0.0)
EV/FCF = -37.46x (Enterprise Value 4.96b / FCF TTM -132.5m)
FCF Yield = -2.67% (FCF TTM -132.5m / Enterprise Value 4.96b)
FCF Margin = -3.28k% (FCF TTM -132.5m / Revenue TTM 4.04m)
Net Margin = -3.99k% (Net Income TTM -161.0m / Revenue TTM 4.04m)
Gross Margin = -15.02% ((Revenue TTM 4.04m - Cost of Revenue TTM 4.65m) / Revenue TTM)
Gross Margin QoQ = -25.50% (prev 5.34%)
Tobins Q-Ratio = 6.27 (Enterprise Value 4.96b / Total Assets 791.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 7.02m)
Taxrate = 21.0% (US default 21%)
NOPAT = -133.3m (EBIT -168.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 24.63 (Total Current Assets 759.5m / Total Current Liabilities 30.8m)
Debt / Equity = 0.01 (Debt 7.02m / totalStockholderEquity, last quarter 752.6m)
Debt / EBITDA = 4.39 (negative EBITDA) (Net Debt -735.1m / EBITDA -167.3m)
Debt / FCF = 5.55 (negative FCF - burning cash) (Net Debt -735.1m / FCF TTM -132.5m)
Total Stockholder Equity = 703.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -20.82% (Net Income -161.0m / Total Assets 791.6m)
RoE = -22.87% (Net Income TTM -161.0m / Total Stockholder Equity 703.8m)
RoCE = -23.87% (EBIT -168.7m / Capital Employed (Equity 703.8m + L.T.Debt 3.00m))
RoIC = -18.90% (negative operating profit) (NOPAT -133.3m / Invested Capital 705.3m)
WACC = 9.47% (E(5.70b)/V(5.70b) * Re(9.48%) + D(7.02m)/V(5.70b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.48% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 7.71%
[DCF] Fair Price = unknown (Cash Flow -132.5m)
EPS Correlation: -85.17 | EPS CAGR: -39.21% | SUE: -0.20 | # QB: 0
Revenue Correlation: 63.36 | Revenue CAGR: 664.9% | SUE: 1.75 | # QB: 2
EPS next Quarter (2026-06-30): EPS=-0.58 | Chg7d=+0.010 | Chg30d=+0.099 | Revisions Net=+5 | Analysts=9
EPS current Year (2026-12-31): EPS=-2.40 | Chg7d=+0.026 | Chg30d=+0.182 | Revisions Net=+9 | Growth EPS=-15.4% | Growth Revenue=+254.9%
EPS next Year (2027-12-31): EPS=-1.99 | Chg7d=-0.138 | Chg30d=+0.214 | Revisions Net=+5 | Growth EPS=+17.0% | Growth Revenue=+880.8%
[Analyst] Revisions Ratio: +1.00 (5 Up / 0 Down within 30d for Next Quarter)
External Resources